Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric P Krenning

Showing results (51-60 of 173) with videos related to

Pageof 18
Sort By:
Journal of Medicinal Chemistry|October 8, 2013
Tumor diagnosis with new 111In-radioligands based on truncated human gastrin releasing peptide sequences: synthesis and preclinical comparisonPanteleimon J Marsouvanidis, Theodosia Maina, Werner Sallegger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2005
Localisation and mechanism of renal retention of radiolabelled somatostatin analoguesMarleen Melis, Eric P Krenning, Bert F Bernard, et al.
Pharmaceutics|September 28, 2024
Diagnosis of Prostate Cancer with a Neurotensin-Bombesin Radioligand Combination-First Preclinical ResultsMaria Bibika, Panagiotis Kanellopoulos, Maritina Rouchota, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|December 15, 2010
Characteristics of SnO2-based 68Ge/68Ga generator and aspects of radiolabelling DOTA-peptidesErik de Blois, Ho Sze Chan, Clive Naidoo, et al.
Journal of Labelled Compounds & Radiopharmaceuticals|April 10, 2019
Comparative evaluation of the new GRPR-antagonist <sup>111</sup> In-SB9 and <sup>111</sup> In-AMBA in prostate cancer models: Implications of in vivo stabilityEmmanouil Lymperis, Aikaterini Kaloudi, Panagiotis Kanellopoulos, et al.
Molecules (Basel, Switzerland)|August 1, 2020
[<sup>99m</sup>Tc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive ModelsPanagiotis Kanellopoulos, Emmanouil Lymperis, Aikaterini Kaloudi, et al.
EJNMMI Research|February 18, 2016
Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [(111)In-DOTA]MG11-first estimates for clinical translationAikaterini Kaloudi, Berthold A Nock, Emmanouil Lymperis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinomaJaap J M Teunissen, Dik J Kwekkeboom, Peter P M Kooij, et al.
Molecules (Basel, Switzerland)|March 16, 2019
Comparing Gly<sup>11</sup>/dAla<sup>11</sup>-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the <sup>111</sup>In-SB3/<sup>111</sup>In-SB4 Radiotracer PairEmmanouil Lymperis, Aikaterini Kaloudi, Panagiotis Kanellopoulos, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 14, 2007
Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organsCristina Müller, Flavio Forrer, Bert F Bernard, et al.
Pageof 18

Showing results (51-60 of 173) with videos related to

Sort By:
Pageof 18
Journal of Medicinal Chemistry|October 8, 2013
Tumor diagnosis with new 111In-radioligands based on truncated human gastrin releasing peptide sequences: synthesis and preclinical comparisonPanteleimon J Marsouvanidis, Theodosia Maina, Werner Sallegger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2005
Localisation and mechanism of renal retention of radiolabelled somatostatin analoguesMarleen Melis, Eric P Krenning, Bert F Bernard, et al.
Pharmaceutics|September 28, 2024
Diagnosis of Prostate Cancer with a Neurotensin-Bombesin Radioligand Combination-First Preclinical ResultsMaria Bibika, Panagiotis Kanellopoulos, Maritina Rouchota, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|December 15, 2010
Characteristics of SnO2-based 68Ge/68Ga generator and aspects of radiolabelling DOTA-peptidesErik de Blois, Ho Sze Chan, Clive Naidoo, et al.
Journal of Labelled Compounds & Radiopharmaceuticals|April 10, 2019
Comparative evaluation of the new GRPR-antagonist <sup>111</sup> In-SB9 and <sup>111</sup> In-AMBA in prostate cancer models: Implications of in vivo stabilityEmmanouil Lymperis, Aikaterini Kaloudi, Panagiotis Kanellopoulos, et al.
Molecules (Basel, Switzerland)|August 1, 2020
[<sup>99m</sup>Tc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive ModelsPanagiotis Kanellopoulos, Emmanouil Lymperis, Aikaterini Kaloudi, et al.
EJNMMI Research|February 18, 2016
Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [(111)In-DOTA]MG11-first estimates for clinical translationAikaterini Kaloudi, Berthold A Nock, Emmanouil Lymperis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinomaJaap J M Teunissen, Dik J Kwekkeboom, Peter P M Kooij, et al.
Molecules (Basel, Switzerland)|March 16, 2019
Comparing Gly<sup>11</sup>/dAla<sup>11</sup>-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the <sup>111</sup>In-SB3/<sup>111</sup>In-SB4 Radiotracer PairEmmanouil Lymperis, Aikaterini Kaloudi, Panagiotis Kanellopoulos, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 14, 2007
Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organsCristina Müller, Flavio Forrer, Bert F Bernard, et al.
Pageof 18